Pharma Industrial India Newsletter [ 2024-06-20]

Open in new window

Pharmaindustrial Mediakit Articles Interviews Appointments Events Magazines

Featured News

Syntegon Introduces Modular Bioprocessing Platform at Achema 2024

Syntegon subsidiary, Pharmatec has rolled out its new Modular Bioprocessing Platform (MBP) at Achema 2024.

Corealis Launches New Facilities in Laval Science Park

Corealis Pharma Inc. has expanded its facilities nestled in the heart of Laval's Biotech City, in the presence of the esteemed Christopher Skeete, Minister for the Economy, and Christine Poirier,...

Medidata Rolls Out Clinical Data Studio to Deliver Safer Trials to Patients

Medidata has unveiled Medidata Clinical Data Studio, a unified experience that unlocks the true power of clinical research data.

ALPLA Group Announces Acquisition of Heinlein Plastik-Technik

The ALPLA Group has been expanding its pharma division ALPLApharma with the acquisition of Heinlein Plastik-Technik GmbH.

TechInvention Lifecare Bags Start-up 50: The Trailblazers Award

TechInvention Lifecare Pvt. Ltd. has secured the coveted 'Start-up 50: The Trailblazers Award' at the 2nd edition of the "Dun & Bradstreet LEAP India Startup Summit 2024," held at the...

Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Wisconsin

Thermo Fisher Scientific’s PPD clinical research business has launched a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin.

Ethypharm Signs Deal with MTPC to Acquire Argatroban Monohydrate

Ethypharm has signed an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra, Arganova, Novastan, Exembol), in Europe.

Lupin Names Abdelaziz Toumi as CEO of its Subsidiary

Lupin has appointed Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS).

Syntegon Showcases New Settle Plate Changer at ACHEMA 2024

Syntegon has showcased an important new development at ACHEMA 2024 that generated a great deal of interest among pharmaceutical manufacturers: the patented Settle Plate Changer (SPC) for automated...

Lupin Signs License and Supply Deal with Fuji for Commercialization of Nextstellis

Lupin has signed a license and supply agreement with OLIC (Thailand) LTD. (OLIC), a subsidiary of the renowned Japanese pharmaceutical company Fuji Pharma Co., Ltd. (Fuji), for marketing Nextstellis...

AGC Biologics Completes New Manufacturing Site at Copenhagen Campus

AGC Biologics has completed its new manufacturing building at Copenhagen campus.

SCHOTT Pharma Launches State-of-the-Art Production Facility in Hungary

SCHOTT Pharma has inaugurated its new production facility for high-quality prefillable glass syringes in Hungary.

ALZpath Signs Licensing Deal with Roche for Use of pTau217 Antibody in Blood Test

ALZpath, Inc. has signed a strategic license agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize an Alzheimer's disease diagnostic blood test.

Gland Pharma Appoints New Executive Chairman and CEO

Gland Pharma Ltd. has announced that Srinivas Sadu has been appointed as Executive Chairman and CEO of the company.

Orchid Pharma Gets DCGI Approval for Enmetazobactam

Orchid Pharma has secured Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.

Cycle Pharmaceuticals Offers All-Cash Proposal to Acquire Vanda Pharmaceuticals

Cycle Pharmaceuticals Ltd. has confirmed that it proposed to the Board of Directors of Vanda Pharmaceuticals, Inc. to acquire 100 percent of Vanda’s issued and outstanding shares for a cash...

Nucleus RadioPharma Receives Series A Extension Funding from AstraZeneca

Nucleus RadioPharma has closed its Series A extension round with new investor AstraZeneca.

AstraZeneca Completes Acquisition of Fusion

AstraZeneca has completed the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

Lupin Gets Tentative Approval from US FDA for Letermovir Tablets

Lupin has secured a tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Letermovir Tablets, 240 mg and 480 mg, to market a...

Syngene Rolls Out New Platform for Enhanced Protein Production

Syngene International Ltd. has introduced its new protein production platform.

Kindeva Expands UK Facilities at Charnwood Campus

Kindeva Drug Delivery has expanded their Loughborough, UK, facilities at the Charnwood Campus Science Innovation and Technology Park.

Bionova Scientific to Expand New Plasmid DNA GMP Facility

Bionova Scientific has decided to expand into plasmid DNA (pDNA) production.

PhoreMost Join Hands with Boehringer Ingelheim

PhoreMost Ltd. has made a multi-project target discovery collaboration with Boehringer Ingelheim.

Aurigene Opens its Biologics Facility in Hyderabad

Aurigene Pharmaceutical Services has inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.

Charting Indias Quest for Innovation in Drug Discovery and Personalised Medicine

India's pharmaceutical sector stands as a global powerhouse, earning the esteemed title of the "Pharmacy of the World" for its unparalleled...

Revolutionizing Patient Data Access in Clinical Trials with ProPharma ClinCHAT

Q: Kindly discuss ProPharma’s latest advancements in Clinical Research and what were the main goals of ProPharma in collaborating with PBL? Being ProPharma,...

This message and any attachments are confidential and privileged and intented for the use of the addressee only. If you have received this communication in error, please notify the sender by replay e-mail and delete this message from your system. Please note that Internet e-mail guarantees neither the confidentiality nor the proper receipt of the message sent. The data deriving from our correspondence with you are included in a file of OMNIMEDIA, S.L. which exclusive purpose is to manage the communications of the company; under the understanding that, in maintaining said correspondence, you authorize the treatment of such data for the mentioned purpose. You are entitled to exercise your rights of access, rectification, cancellation and opposition by addressing such written application to address C/ Pollensa, 2, Edif. Artemisa of. 12 de LA ROZAS (28290 - MADRID) enclosing your NIF or identifying document photocopies of.

Unsubscribe